CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount of $500.00 thousand for the 12-month period ending 2020-12-26, per its 10-K filed 2022-02-16.
Discontinued › Notes › Investments › Debt and Equity Securities › Equity Securities without Readily Determinable Fair Value, Annual Amount
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount · last filed 2022-02-16
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. equity securities without readily determinable fair value, upward price adjustment, annual amount for fiscal 2020 was $500.00K, a 400.00% increase from fiscal 2019.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. equity securities without readily determinable fair value, upward price adjustment, annual amount for fiscal 2019 was $100.00K.
| Period end | Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount 12 month |
|---|---|
| 2020-12-26 | $500.00K 10-K · filed 2022-02-16 |
| 2019-12-28 | $100.00K 10-K · filed 2022-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |